What is the ticker symbol for VYNE Therapeutics?

VYNE Therapeutics trades under the ticker VYNE on NASDAQ.

What sector does VYNE Therapeutics operate in?

VYNE Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VYNE in a portfolio?

PortView shows VYNE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

VYNE Therapeutics (VYNE) Stock Analysis

NASDAQHealthcareBiotechnology

$28.56+0.00%

1-year price historyRange $14.35 – $73.00

52-week range$28.56

$14.03$74.47

Track VYNE in your portfolio for free · Portfolio tracker

What VYNE Therapeutics does

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.

Key metrics

Market cap

$19.07M

P/E (TTM)

-43.27

EPS (TTM)

$-0.66

Beta

2.01

Dividend yield

105.35%

Revenue / share

$0.56

50-day avg

$34.03

200-day avg

$28.60

52-week high

$74.47

52-week low

$14.03

CEO

David T. Domzalski

ETFs linked to VYNE

Broad-market and Healthcare sector ETFs an investor holding VYNE Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how VYNE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze VYNE in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for VYNE Therapeutics?: VYNE Therapeutics trades under the ticker VYNE on NASDAQ.
Which exchange is VYNE listed on?: VYNE is listed on NASDAQ.
What sector does VYNE Therapeutics operate in?: VYNE Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze VYNE in a portfolio?: PortView shows VYNE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.